AE Risk Examined for Abiraterone, Enzalutamide in Prostate Cancer
Risk for metabolic or cardiovascular adverse events increased for men receiving abiraterone or enzalutamide for advanced disease
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Endocrinology, Oncology, Pharmacy, Urology, Journal, Source Type: news
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Endocrinology | Heart | Prostate Cancer | Urology & Nephrology